Navigation Links
PTC Therapeutics to Showcase Breadth of Pipeline at Upcoming R&D Day
Date:10/19/2013

ments:                   
Any statements in this press release about future expectations, plans and prospects for the Company, the development of and potential market for the Company's product candidates and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan" "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Forward-looking statements involve substantial risks and uncertainties that could cause our future results, performance or achievements to differ significantly from those expressed or implied by these forward-looking statements. Such risks and uncertainties include, among others, those related to the initiation and conduct of clinical trials, availability of data from clinical trials, expectations for regulatory approvals, our scientific approach and general development progress, the availability or commercial potential of our product candidates and other factors discussed in the "Risk Factors" in the most recent Quarterly Report, which is on file with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the Company's views only as of the date of this release. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of this release.


'/>"/>
SOURCE PTC Therapeutics, Inc.
Copyright2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
2. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
3. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
4. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
5. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
6. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
7. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
8. Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
9. Frost & Sullivan: High Uptake of New Drug Therapies and Aging Population Expansion Keep the U.S. Retinal Therapeutics Market Buoyant
10. Zenobia Therapeutics, Inc. And BioBlocks, Inc. Announce Sale Of A Joint Fragment Library Ideal For Screening By All Popular Methods
11. New Forecast Shows Global Protein Therapeutics Market to Reach $143.4 Billion by 2015
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... WASHINGTON , May 22, 2015  The ... certain diagnosed victims of mesothelioma get the best ... making certain individuals with this rare cancer caused ... the most up-to-date information related to treatment options ... information please call the Mesothelioma Victims Center anytime ...
(Date:5/22/2015)... --  InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the ... announced that its CGuard TM Embolic Prevention System reported ... Piotr Musialek , at the EuroPCR conference on ... PARADIGM, an investigator-initiated P rospective evaluation of ... revascularization I n symptomatic and increased-risk asymptomatic carotid ...
(Date:5/22/2015)... , May 22, 2015  In a sweeping ... the U.S., T1D Exchange researchers conclude that ... type 1 diabetes across all age groups, but especially ... most up-to-date picture of diabetes treatment, underscoring the need ... and technologies that can help type 1 patients achieve ...
Breaking Medicine Technology:Mesothelioma Victims Center Calls Attention to a Recent Medical Article About a New Drug That Could Slow the Progression of Mesothelioma and Allow People to Live Longer 2Mesothelioma Victims Center Calls Attention to a Recent Medical Article About a New Drug That Could Slow the Progression of Mesothelioma and Allow People to Live Longer 3Mesothelioma Victims Center Calls Attention to a Recent Medical Article About a New Drug That Could Slow the Progression of Mesothelioma and Allow People to Live Longer 4Mesothelioma Victims Center Calls Attention to a Recent Medical Article About a New Drug That Could Slow the Progression of Mesothelioma and Allow People to Live Longer 5InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 2InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 3InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 4Study Reveals Poor Disease Control Among Adolescents and Young Adults with Type 1 Diabetes 2Study Reveals Poor Disease Control Among Adolescents and Young Adults with Type 1 Diabetes 3Study Reveals Poor Disease Control Among Adolescents and Young Adults with Type 1 Diabetes 4Study Reveals Poor Disease Control Among Adolescents and Young Adults with Type 1 Diabetes 5
... In a platform presentation at the 46th annual meeting ... (EASD) in Stockholm, investigators for Biodel Inc. (Nasdaq: ... clinical study evaluating a new pH-neutral formulation of Linjeta™ ... Research, Neuss, Germany) and colleagues reported that the new ...
... (Nasdaq: MYL ) today announced that its ... the U.S. Food and Drug Administration (FDA) for its ... mg, 1 mg and 5 mg, the generic version ... in people who have received certain organ transplants. ...
Cached Medicine Technology:Results of Linjeta™ Study Versus Insulin Lispro Reported Today in Platform Presentation at EASD Annual Meeting 2Results of Linjeta™ Study Versus Insulin Lispro Reported Today in Platform Presentation at EASD Annual Meeting 3
(Date:5/22/2015)... New York, NY (PRWEB) May 22, 2015 ... abstract entitled “Positivity Rates and Genotype Results in ‘Baby ... Action: Results from a Nationwide Lab Test Database” at Digestive ... conducted by Medivo’s Clinical Affairs and Analytics team members Carol ... Dhaliwal, MD; and Andrea Parker, MSI, along with Nancy Reau, ...
(Date:5/22/2015)... DMG Productions announces the upcoming airing of Innovations ... May 29, 2015 at 7:30 a.m. ET and 7:30 ... Innovations will explore Interstate Restoration, a company dedicated to ... recovery and restoration. , Additionally, the series will focus ... and deliver training and education in the areas of ...
(Date:5/22/2015)... 2015 In April 2006, Veatch Consulting ... 9 years they have concentrated their focus to working ... Canada. Because of this growth and their goals to ... in Denver, Colorado, Cleveland, Ohio, Houston, Texas and now ... new dental offices, dental start ups, orthodontic practices, pediatric ...
(Date:5/22/2015)... May 22, 2015 Puritan Medical ... for the medical, diagnostic, environmental, and forensics industries ... of products in the US. At a time ... outside the US, Puritan remains committed to designing ... their Guilford, Maine facility. , Since 1919, Puritan ...
(Date:5/22/2015)... Viejo, CA (PRWEB) May 22, 2015 ... editable lower thirds designed exclusively for Final Cut Pro ... compatible with any design. , Intuitive on-screen-controls allow ... unique lower third. Reflections, colors, layouts, and much more ... Inspector window. , Pro3rd Impression comes ...
Breaking Medicine News(10 mins):Health News:Medivo Study Finds HCV Positivity Rates are 250% Higher Among Baby Boomers 2Health News:New Episode of Innovations Airing Friday, May 29, 2015 Via Discovery Channel 2Health News:Maine Swab Company Celebrates 96 Years of American-made Products 2Health News:Developers at Pixel Film Studios Release Pro3rd Impression for Final Cut Pro X. 2
... , CUPERTINO, Calif., July 27 ... quarter 2009 financial results press release, you are invited to listen ... internet on Monday, August 3, 2009 at 4:30 pm Eastern Time ... http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO ) , , A live audio webcast ...
... of serious complications drop with intensive therapy, study shows ... controlling blood sugar levels and taking medications that lower ... can significantly reduce their risk of developing the most ... , In a study appearing in the July 27 ...
... 27 Danaher Corporation (NYSE: DHR ) announced today that ... effective as of the end of 2009. , , ... joining Danaher in 2000. , , "Phil ... portfolio over the past nine years," said H. Lawrence Culp, Jr., President ...
... , , ATLANTA, July 27 ... diagnosis and treatment of infertility with ovulation induction and insemination, surgery ... financial aspects. Discussions include information about age related infertility, fallopian tube ... donor eggs. , , You will also ...
... , , , ... Program officials announced today that Tennessee residents have saved over ... launch of the free statewide prescription assistance program. Tennessee Drug ... in May 2007. The program has no restrictions to membership, no ...
... , , MINNEAPOLIS, July 27 ... the world,s population, often resulting in patches of dry skin, and little ... in the teenage years but may continue throughout adulthood. There is ... Alan B. Fleischer, professor and chair of the department of dermatology at ...
Cached Medicine News:Health News:DURECT Corporation Invites You to Join Its Second Quarter 2009 Earnings Conference Call 2Health News:Tight Management of Type 1 Diabetes Worth the Effort 2Health News:Tight Management of Type 1 Diabetes Worth the Effort 3Health News:Tennessee Drug Card Has Saved Residents Over $7.3 Million 2Health News:What Is Keratosis Pilaris (KP)? 2
... SurgiGraphic 1027, with a Carbon Fiber ... designed for superior C-arm access, safety ... design means C-Arm utilization is quick ... exposure is minimized resulting in a ...
... The SurgiGraphic 6000 ... the tabletop for precise ... Float allows for immediate ... moving the C-Arm, making ...
... IMPLANT SYSTEM is a unique three-piece implant ... 1st metatarsal phalangeal joint resulting from osteoarthritis, ... a previous arthroplasty. The implant is ... superior function and longevity. With a ...
... play an important part in our daily ... rheumatic changes can cause severe handicaps. A ... finger-joint prostheses was to produce a reconstructed ... function as nearly possible.,The cementless RM Finger ...
Medicine Products: